MHC Class II deficiency is a rare primary immunodeficiency disease characterized by absent HLA Class II expression resulting in CD4 lymphopenia, lack of Ag-specific responses and recurrent infection. Without successful allogeneic SCT, most children succumb to infection within the first decade of life. To date, alternative donor transplants for this disorder have been inferior to SCT for other forms of combined immunodeficiency disease due to an increased incidence of graft rejection, GVHD and death from infections generally acquired before haematopoietic cell transplantation. This study details the transplant outcome of 16 affected children consecutively transplanted at four centers since 1990, 8 of whom required mechanical ventilation pretransplant. Stem cells were derived from an HLA-mismatched family member (n ¼ 10), an HLA-matched unrelated adult donor (n ¼ 4), or an unrelated cord blood donor (n ¼ 2). Graft failure occurred in five children, all of whom underwent a second SCT. Six patients developed acute GVHD although no patient developed chronic GVHD after primary transplantation. CD4 T-cell reconstitution remained below the normal range for age, suggesting defective thymopoiesis after allo-SCT. Nonetheless, 69% of children survive without GVHD at a median follow-up of 5.7 years, indicating improved outcomes compared with previous studies.
INTRODUCTION
MHC Class II deficiency, also known as Type II Bare Lymphocyte Syndrome, is a rare form of autosomal recessive combined immunodeficiency disease currently curable only by allo-SCT. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Patients with this disease possess normal MHC Class II genes, but have mutations within one of four transactivating genes that control their expression (reviewed in Reith and Mach 2 and Villard et al.
3
). Over 85% of affected children have mutations in genes encoding subunits of regulatory factor X (RFXANK, RFXAP or RFX5), a protein complex that binds to the MHC Class II promoter and activates transcription. The remaining patients have defects of the Class II transactivator, a factor that regulates constitutive and IFN-g upregulation of MHC Class II antigens (reviewed in Reith and Mach 2 and Villard et al.
). Patients with MHC Class II deficiency generally have severe CD4 T-cell lymphopenia, hypogammaglobulinemia and lack Ag-specific responses resulting in chronic diarrhea, recurrent viral, parasitic and bacterial infections, and failure to thrive. 1, 4, 5, 7 Although recent reports of allo-SCT for this disease have shown improved survival following HLA-matched related donor transplantation, 8, 9 for those patients lacking such a donor survival of p50% has been reported. 4, 5, [7] [8] [9] The rarity of this disease challenges physicians making transplant decisions for affected children who lack a well-matched family donor. We have collected data for 16 consecutive patients transplanted at four centers in Europe and North America since 1990 to characterize outcomes following alternative donor SCT for this disorder. With 69% (11/16 ) overall survival at a median followup of 5.6 years, our experience indicates improved outcomes after such transplants, but we highlight notable difficulties with graft rejection, and less than optimal CD4 T-cell reconstitution following SCT in this condition.
MATERIALS AND METHODS
Patient characteristics, preparative regimen, graft characteristics, GVHD prophylaxis and supportive care
Sixteen consecutive patients with MHC II Class deficiency were referred to the University of Ulm (n ¼ 8), Great Ormond Street Hospital (n ¼ 4), Cincinnati Children's Hospital Medical Center (n ¼ 2) and Memorial Sloan-Kettering Cancer Center (n ¼ 2) between 1990 and 2011 for SCT. The demographics and clinical characteristics of the seven females and nine males are shown in Table 1 . All patients were diagnosed by the absence of MHC Class II expression on peripheral blood monocytes and B cells by flow cytometry. Patients 12 and 16 had mutations in the RFXAP and RFXANK genes, respectively. Mutations in the other patients are unknown. Median age (range) at time of initial transplant was 1.6 (0.5-4) years. All but one patient had X1 life-threatening infection before transplant, including pneumonia in 14 patients, 8 of whom required mechanical ventilation before SCT. In addition to pneumonia, the majority of patients had infectious diarrhea and failure to thrive. Patient 11 had two episodes of PCP pneumonia and 1 episode of ECHO virus meningoencephalitis before SCT. Patient 15 had rubella viremia before transplantation.
Stem cell donor and preparative regimen. Transplant donors were HLA-Ag-mismatched family members (n ¼ 10), HLA-allele-matched (10/10) unrelated adult volunteer donors (n ¼ 4) or unrelated cord blood donors (n ¼ 2) ( Table 2 ). HLA typing for cord blood units was defined by serological typing for HLA A and B antigens and high-resolution molecular typing for HLA DRb1.
Seven patients received T-cell-depleted SCT, six of whom received BU (X16 mg/kg over 4 days), combined with thiotepa and fludarabine (n ¼ 3), thiotepa and CY (n ¼ 1), CY and fludarabine (n ¼ 1), or CY alone (n ¼ 1). Recipients of T-cell-depleted SCT received anti-thymocyte globulin (n ¼ 6) or anti-CD52 (Campath 1H, n ¼ 1) to prevent graft failure. Recipients of an unmodified BM or PBSCT were cytoreduced with BU, fludarabine, CY (n ¼ 2), thiotepa and CY (n ¼ 1), melphalan, fludarabine and anti-CD52 (n ¼ 2), fludarabine, CY, anti-CD45 and anti-CD52 (n ¼ 1), or low-dose CY, fludarabin 200 cGy of single-dose TBI and post-transplant CY. Posttransplant prophylaxis against GVHD included combinations of cyclosporin or tacrolimus and mycophenolic acid. The two cord blood recipients received treosulfan and fludarabine without serotherapy. Table 2 . Graft characteristics. Nine patients received a T-cell replete BM (n ¼ 5), peripheral blood (n ¼ 2), or cord blood (n ¼ 2) SCT. Seven patients received a T-cell-depleted SCT derived from peripheral blood (n ¼ 6) or BM (n ¼ 1). Peripheral blood was T cell depleted by CD34 þ selection followed by sheep red blood cells rosetting. BM was T cell depleted by soybean agglutination followed by sheep RBC rosetting. One patient received a CD34 þ selected PBSC transplant combined with 10 8 /kg addback T cells derived from the CD34 À fraction.
GVHD prophylaxis and evaluation
All recipients of an unmodified graft received a calcineurin-based regimen to prevent GVHD (Table 2b ). Patient 13 who received add-back T cells following a T-cell-depleted graft received additional GVHD prophylaxis with CyA, mycophenolic acid and Campath 1H. Acute GVHD was defined as any GVHD occurring o100 days post-transplant and was graded according to the Glucksberg criteria. 14 Chronic GVHD was graded as limited or extensive according to the criteria of Sullivan et al. 15 Engraftment, graft failure and donor chimerism. Engraftment was defined as the first of three consecutive days of an ANC of X500 cells/mL. Primary graft failure was defined as failure to achieve an ANC of X500 cells/mL by day 28 after haematopoietic cell transplantation (HCT). Secondary graft failure was defined as failure to maintain an ANC 4500 cells/mL after achieving engraftment. Stem cell boosts were defined as transplants given to patients with evidence of T-and B-cell donor engraftment but slow recovery of neutrophils following a T-cell-depleted graft. Complete donor chimerism was defined by 495% MHC Class II expression on circulating B cells and monocytes. Lineage-specific chimerism was performed in some patients by assessment of STRs in circulating lymphoid and myeloid cells.
Supportive care. All patients were transplanted in single room reverse isolation with filtered air. Routine HSV, fungal and PCP prophylaxis was given to all patients. Neutropenic patients with persistent fever despite 72 h of broad-spectrum antibiotics received empiric anti-fungal therapy. Pre-emptive or prophylactic treatment to prevent CMV was given as per institutional guidelines. All patients received intravenous gammaglobulin (IVIG) pre and post SCT, the duration of which was guided by trough IgG levels and response to post SCT immunizations.
Biostatistics. Fisher's exact test for qualitative variables and the Wilcoxon rank-sum test for quantitative variables were used for comparisons between groups. Only P-values o0.05 were considered statistically significant. Table 1 shows the pre-HCT immunophenotype and function of the transplanted patients. At the time of SCT, the median (range) CD4 and CD8 T cells/mL were 507 (80-1250) and 740 (123-3842) cells/mL, respectively. There was no significant difference in CD4 T, CD8 T, or CD56 CD16 natural killer cell numbers in patients who did or did not achieve durable engraftment following an initial graft. Six patients had a PHA X50% of normal and four patients had a severely impaired PHA response. A pooled mixed lymphocyte response was normal in five of six patients in whom it was tested. Engraftment Thirteen patients engrafted following their initial transplant, two of whom developed secondary graft failure (Tables 2a and b) . Durable engraftment was observed in four of seven and seven of nine recipients of a T-cell-depleted or unmodified grafts, respectively (P ¼ NS). Five patients underwent a second transplant, four derived from the original donor (Table 2 ). Time to second transplant was a median (range) of 58 days (19-651) days after the first SCT. Despite engraftment, only two of five recipients of a subsequent graft survive for long-term. (Table 2) . Three patients developed grade I skin GVHD following HLA-mismatched related TCD PBSC transplant, one patient developed fatal grade IV following unmodified unrelated peripheral blood transplant, and two patients developed grade I (n ¼ 1) or II (n ¼ 1) GVHD following unrelated cord blood SCT. One patient developed grade IV GVHD following a secondary graft which was partially T-cell-depleted.
RESULTS

Pretransplant immunological studies
Chronic GVHD Of the 11 patients evaluable for chronic GVHD, none developed this complication following a primary HCT. One patient developed fatal chronic GvHD after a subsequent transplant for graft rejection (Table 2a) .
Survival
As of 6/25/12, 11 of 16 patients survive, one with developmental delay at a median of 5.8 (0.35-22.1) þ years post HCT. Seven patients survive following their initial SCT, two following a second SCT and two following a TCD boost because of slow engraftment following the primary SCT.
Cause of death Five of 16 patients died. Following a primary transplant, the causes of death were GVHD and multi-organ failure (day þ 39), adenovirus pneumonia (day þ 329) or complications from acute GVHD (day þ 120). Two children died following a second SCT, one because of chronic GVHD with invasive Aspergillus after 3 years and the other because of autoimmune hemolytic anemia and CMV disease 2.5 years after SCT (Tables 2a and b ).
Chimerism
Ten of 11 surviving patients have 495% class II expression on B cells and monocytes after allo-SCT (data not shown). The most recently transplanted patient achieved 100% donor T-cell chimerism and 50% donor monocytes 3 months post HCT.
Immune reconstitution Figure 1 demonstrates the early (0-2 years) and extended (0-5 year) recovery of CD4 cells/mL in T-cell-depleted (Figures 1a and b) compared with T-cell replete (Figures 1c and d) SCT recipients. The majority of surviving patients achieved CD4 cell counts 4200 cell/mL, but levels remained below the normal range for age. 16 Although some patients developed circulating CD4 T cells within the first 2 years post HCT (Figures 1a and c) , counts in many of these patients subsequently declined. The most robust early CD4 T-cell count was observed in patient 12 who received a cord blood SCT without serotherapy. Figures 2a and b . demonstrate the absolute number ( Figure 2a ) and proportion of CD4 þ CD45RA þ (Figure 2b ) cells, respectively. In all patients, these values were below the normal range for age. 16 Table 3 shows the immunological and clinical status of surviving patients at last follow-up. All patients immunized with tetanus toxoid seroconverted as did 5/5 patients immunized with the protein-conjugated Haemophilus influenza vaccine. Patient 1 responded to all vaccines administered including measles and rubella following the live attenuated measles, mumps and rubella (MMR) vaccine administered at 27 months post HCT. He responded to mumps following a second MMR. His titers against measles, mumps and rubella were 0.05, 0.03 and 0.04 (before the first vaccine), 1.45, 0.11 and 124 IU/mL (following the initial MMR), and 3.28, 2.18 and 237 IU/mL after the second MMR, respectively. DISCUSSION MHC Class II deficiency is difficult to transplant, with increased regimen-related toxicity, serious opportunistic infections, graft rejection and GVHD, even in the context of an HLA-matched sibling graft. [1] [2] [3] [4] [6] [7] [8] [9] [10] [11] [12] For certain inherited T-cell immunodeficiencies, unconditioned transplantation using HLA-identical grafts can be successful because host cellular immunity is insufficient to cause graft rejection (reviewed in Small et al. 17 ). However, in MHC class II deficiency, residual host immunity is sufficient to reject donor grafts in the absence of preconditioning. Experience from animal studies confirms that MHC Class IIdeficient mice are capable of rejecting allogeneic grafts as rapidly as MHC intact mice. 18 Our data combined with published literature suggest that the use of BU (albeit without routine quantification of levels or dose adjustment) combined with CY even in the presence of additional immunosuppression is insufficient to yield reproducible engraftment in patients with this disease. Although four of seven recipients of a T-cell-depleted HCT in this series survive, three patients required a subsequent transplant for graft failure and two patients required T-cell-depleted boosts for delayed neutrophil engraftment. Following a T-replete graft, 2/9 patients rejected their transplant. #1  #3  #8  #11  #12  #14  #15   #3  #8  #11  #12  #14  #15   #2  #5  #6  #7   #1  #2  #5  #6 Following HLA-matched related SCT for MHC Class II deficiency disease, survival rates of 40-80% have been reported. In contrast, unrelated and HLA-mismatched transplant outcomes of p50% have been observed. [1] [2] [3] [4] [6] [7] [8] [9] [10] Ouedeerni et al. 7 recently published results of a single-center study of 23 patients with MHC Class II deficiency due to a RFXANK mutation. Despite myeloablative conditioning (BU/CY) in all patients followed by a T-replete graft, only 40% of patients survived following HLA-mismatched related transplantation. One recipient of an unrelated cord blood graft (HLA 9/10 ) in this series achieved only 1% donor chimerism and survives in poor condition. Successful cord blood SCTs following rejection of TCD HLA-mismatched related SCT for this disease have been reported. 11, 12 Al Mousa et al. 9 evaluated the results of 30 children with MHC Class II deficiency who received HLA-matched related family grafts, 1-Ag HLA-mismatched family grafts (n ¼ 3) or unrelated cord blood donation (n ¼ 1). The majority of patients received myeloablative conditioning, primarily with combinations of BU, CY and etoposide. Twelve patients received reduced intensity conditioning consisting of fludarabine, melphalan and ATG. At a median follow-up of 6.3 years, survival was 66% for the entire group and 76% in HLA-matched related HCT recipients. None of the patients who received reduced intensity conditioning followed by an HLA-mismatched related HCT survived, nor did the cord blood graft recipient. Two of three patients transplanted before the onset of infection due to previous family history developed graft failure, one of whom died. Despite successful engraftment, immune reconstitution, in particular CD4 T-cell recovery, has been suboptimal in the majority of patients transplanted for MHC Class II deficiency. 2, 7, 9 In our study, most patients only achieved CD4 levels in the 200-400/mL range, although T-cell responses to mitogens normalized in all long-term survivors, and the majority of immunized patients have had satisfactory vaccine responses. Caution should, however, be exercised in deciding when to withdraw antimicrobial prophylaxis and Ig-replacement therapy, as well as the time to initiate immunization with live attenuated vaccine in this patient population. Patient 10 developed late disseminated wild-type varicella zoster infection necessitating mechanical ventilation despite evidence of active thymopoiesis (based on the presence of naive cells and TREC levels), normal T-cell responses to mitogens and Ab response following tetanus vaccination. This patient required reinstitution of Ig-replacement therapy. Although patient 1 responded fully to measles and rubella, he did not respond to mumps following initial administration of a live, attenuated MMR vaccine. Thus, despite full donor engraftment and satisfactory laboratory parameters of immune reconstitution, some patients with MHC Class II deficiency may remain susceptible to serious infection for prolonged periods after transplantation. This raises important questions about the mechanism of immune reconstitution in this disease, and the role of MHC class II expression on non-haematopoietic cells. Interestingly, acquisition of a CD4 count of 1500 cells/mL was achieved in patient 12 following an unrelated cord blood HCT administered following a treosulfan-based regimen in the absence of ATG or Campath 1H. This is similar to other children transplanted with cord blood for hematologic malignancies or other PID using cord blood without in vivo T-cell depletion. 13 Selection and development of CD4 T cells requires thymic expression of MHC class II. It has been postulated that patients with MCH Class II deficiency may have residual MHC class II expression on cortical thymic epithelium, or that donor-derived myeloid cells provide sufficient correction of MHC expression following transplantation to allow CD4 T-cell selection. Recent studies in mice suggest an alternative pathway for CD4 T-cell development, whereby donor-derived thymocytes expressing MHC class II facilitate CD4 T-cell selection in the thymus. 18 The concept of multiple avenues of T-cell maturation in the thymus, mediated via thymic epithelial cells, thymocytes or as yet undefined lineages would explain why patients with MHC Class II deficiency can support thymopoiesis and T-cell reconstitution (albeit partial in many cases) after transplantation despite persistent deficiency of MHC II expression in non-haematopoietic lineages. 20 It should be noted that all surviving patients in this study remained deficient in naive T-cell numbers. In the HLA-matched family donor setting, transfer of mature donor T cells expanding in the recipient may contribute to more rapid reconstitution, in contrast to T-cell-depleted transplants, where T-cell reconstitution resides predominantly on de novo thymopoiesis. This may be similarly of importance in unrelated donor grafting when serotherapy is used for in vivo T-cell depletion of donor T cells to prevent GVHD. Finally, although residual immunodeficiency may be primarily due to suboptimal reconstitution of the CD4 T-cell compartment, defective MHC expression on other tissues such as the vascular endothelium may continue cause impaired Ag presentation during infective episodes. 15 The full clinical significance of such defects will only be determined by careful follow-up of patients transplanted in infancy or early childhood, but on the basis of our experience we advocate early SCT with the best available donor for children with this condition.
